research Management of Toxicities of Targeted Therapies
Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
Search
for
Sort by
Research
90-120 / 1000+ results 
research ESGCT and FSGT Collaborative Congress Helsinki, Finland September 17–20, 2015 Abstracts
The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.
research Quoi de neuf en recherche dermatologique ?
2011 dermatological research found new skin aging markers, hair loss causes, skin defense mechanisms, and potential for new treatments.
research Hair Oils May Worsen Seborrheic Dermatitis in Black Patients
Hair oils can worsen seborrheic dermatitis in black patients.
research The role of janus kinases in the treatment of autoimmune skin diseases
Janus kinase inhibitors show promise in treating autoimmune skin diseases.
research Scaffolds for epithelial and hair follicle regeneration
Electrospun matrices help regenerate skin and hair follicles using PCL and collagen scaffolds.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research STUDIES ON THE ANTIMICROBIAL ACTIVITY OF EVOLVULUS ALSINOIDES, MURRAYA KOENIGII, LAWSONIA INERMIS, HIBISCUS ROSA-SINENSIS, AZADIRACHTA INDICA AGAINST MALASSEZIA FURFUR USING FRACTIONAL FACTORIAL DESIGN
The study found that a specific combination of five medicinal plants effectively inhibits the fungus that causes dandruff.
research Probing androgen receptor co-factor selectivity profiles: a chemical tool to determine cross-talk between androgen receptor and β-catenin in vivo
PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
research 'The Byzantine logic of patent law jurisprudence': patent protection for dosage regimes revisited
UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.
research Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.
research Regulatory T Cell Heterogeneity in the Steady State and Tumor
Regulatory T cells adapt to different environments to control inflammation and support tissue repair.
research Hair follicle gene expression profiling in the SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS)
Hair follicles can be used to study gene expression and understand conditions like COPD.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
This Phase 3 clinical trial investigates the efficacy and safety of ritlecitinib at 50 mg and 100 mg doses for treating severe alopecia areata in patients aged 12 and older with at least 50% scalp hair loss. The study involves 550 participants and uses an innovative design with external and synthetic placebo control groups, eliminating the need for new patients to be randomized to a placebo. The primary outcome is measured by the Severity of Alopecia Tool (SALT) score, with the main goal being to compare the effectiveness of the 100 mg dose against the 50 mg dose and placebo over 48 weeks. The trial aims to address the unmet need for more effective AA treatments, as current therapies often fall short in efficacy.
research Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
This narrative review examines the dermatologic comorbidities associated with atopic dermatitis (AD), such as allergic contact dermatitis, alopecia areata, chronic spontaneous urticaria, hidradenitis suppurativa, psoriasis, prurigo nodularis, and vitiligo. It highlights the importance of recognizing these comorbidities for effective management and suggests that therapies targeting shared immunological mechanisms, like JAK inhibitors and dupilumab, show promise in treating both AD and its comorbidities. The review emphasizes the need for further research to optimize treatment strategies and explore combination therapies for patients with AD and associated dermatological conditions.
research Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel
Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
research Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
AA patients with comorbid conditions face more severe hair loss and need specific treatments.
research Scalp cooling therapy for chemotherapy-induced hair loss in Asian patients with breast or gynecological cancers – a tertiary institution experience
Scalp cooling therapy helps preserve hair during chemotherapy for most patients.
research Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey
Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Farmácia Militar do Laboratório Nacional do Medicamento, Porto e Serviços Farmacêuticos do Centro Hospitalar Universitário do Porto (Hospital de Santo António), EPE, Porto
Pharmacists play a crucial role in patient care and optimizing treatment outcomes.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Histopathological Study of Epithelial, Melanocytic And Adnexal Tumors Of Skin- A Retrospective Study In A Tertiary Care Centre
Most skin tumors in the study were benign, with squamous cell carcinoma being the most common malignant type.
research Antioxidant potential, anti-inflammatory activity, antidiabetic and cardioprotective effect of Microsechium helleri(Peyr.) Cong.
Microsechium helleri extract has antioxidant, anti-inflammatory, antidiabetic, and heart-protective benefits.
research Dermal EZH2 simultaneously orchestrates Wnt/β-catenin signaling dependent dermal differentiation and retinoic acid signaling dependent epidermal proliferation during murine skin development
Ezh2 controls skin development by balancing signals for dermal and epidermal growth.
research Dermal EZH2 simultaneously orchestrates dermal differentiation and epidermal proliferation during murine skin development
Dermal EZH2 controls skin cell growth and differentiation in mice.
research Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies
Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
research SAT0200 UNUSUAL SYSTEMIC LUPUS ERYTHEMATOSUS/SJOEGREN'S SYNDROME PHENOTYPE IN A PATIENT WITH A TNFAIP3 GENE MUTATION
A TNFAIP3 gene mutation can cause unusual and varied symptoms of lupus and Sjogren's syndrome.